Clinical trials: Lung Fibrosis Interstitial
Pulmonary Fibrosis, Scleroderma, Systemic
Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma
Clinical and experimental studies suggest that bosentan could delay the progression of interstitial lung disease (ILD) associated with systemic sclerosis (SSc), a condition for which no established efficacious treatment is…
- Trial name
- NCT00070590
- Testing
- Bosentan
- Volunteers
- 132 people
- Sponsor
- Actelion
Idiopathic Pulmonary Fibrosis, Lung; Disease, Interstitial, With Fibrosis
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers
This is a phase 1, randomized, First in Human (FIH), double-blinded, placebo-controlled study to assess the safety, tolerability, and PK of RSN0402 in healthy volunteers.
- Trial name
- NCT06482190
- Testing
- RSN0402 Part 1, RSN0402 Part 2
- Where
- 3 sites in Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shenzhen Resproly Biopharmaceutical Co., Ltd
Idiopathic Pulmonary Fibrosis
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Primary Objective: To assess in adult patients with Idiopathic Pulmonary Fibrosis (IPF) the safety and tolerability of ascending doses of SAR156597 administered subcutaneously (SC) once weekly over a 6-week period.
- Trial name
- NCT01529853
- Testing
- SAR156597
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 24 people
- Sponsor
- Sanofi
Idiopathic Pulmonary Fibrosis
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT01629667
- Testing
- Tralokinumab
- Where
- 45 sites in United States, Australia and 4 more
- Volunteers
- 409 people
- Sponsor
- MedImmune LLC
Pulmonary Fibrosis
The BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With Pulmonary Fibrosis Who Take Nintedanib
The aim of this study is to describe patients' satisfaction with Patient Support Program (Balance Program), Quality of Life and depression symptoms, dosing pattern, disease symptoms, adverse events and nintedanib discontinuation…
- Trial name
- NCT06912659
- Where
- Spain
- Volunteers
- 166 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
- Conditions
- Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
- Trial name
- TETON-OLE (NCT04905693)
- Testing
- Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
- Where
- 192 sites in United States, Argentina and 16 more
- Volunteers
- 1,850 people
- Sponsor
- United Therapeutics
Idiopathic Pulmonary Fibrosis
D2212C00002 J-Phase II Study
The purpose of the study is to evaluate the safety and tolerability of multiple-doses of tralokinumab in Japanese patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT02036580
- Testing
- tralokinumab cohort 1, tralokinumab cohort 2
- Where
- 5 sites in Japan
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Idiopathic Pulmonary Fibrosis
Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)
To provide early access and to evaluate the safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT02171156
- Testing
- nintedanib
- Where
- 7 sites in United States
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis
This is an active surveillance study to monitor the real world safety of nintedanib in Indian patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT03047031
- Testing
- Nintedanib, Pirfenidone
- Where
- 8 sites in India
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)
The primary objectives of this study are to determine the effect of simtuzumab (GS-6624) on progression-free survival (PFS) as determined by either a categorical decline in forced vital capacity (FVC) or all-cause mortality, in…
- Trial name
- RAINIER (NCT01769196)
- Testing
- Simtuzumab
- Where
- 175 sites in United States, Australia and 12 more
- Volunteers
- 544 people
- Sponsor
- Gilead Sciences
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients
The main goal of this phase llb study is to compare the efficacy and safety of two doses of HEC585 tablets with placebo which is a look-alike substance that contains no active drug in patients with progressive fibrosing…
- Trial name
- NCT05139719
- Testing
- HEC585 dose A, HEC585 dose B
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Idiopathic Pulmonary Fibrosis
Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FG-3019, a therapeutic antibody designed to block the pro-fibrotic activity of connective tissue growth factor…
- Trial name
- NCT00074698
- Testing
- FG-3019
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Kyntra Bio
Idiopathic Pulmonary Fibrosis
Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A multicenter randomized, double-blind, parallel group, placebo-controlled, exploratory phase IIa study in subjects with Idiopathic Pulmonary Fibrosis (IPF) to evaluate safety, tolerability, pharmacokinetics (PK), and…
- Trial name
- NCT02738801
- Testing
- GLPG1690 600 mg QD
- Where
- 8 sites in Ukraine, United Kingdom
- Volunteers
- 23 people
- Sponsor
- Lakefront Biotherapeutics NV
Scleroderma
Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis
The purpose of this study was to evaluate the safety of Dasatininb in the treatment of scleroderma pulmonary interstitial fibrosis.
- Trial name
- NCT00764309
- Testing
- dasatinib
- Where
- 13 sites in United States
- Volunteers
- 47 people
- Sponsor
- Bristol-Myers Squibb
Pulmonary Alveolar Proteinosis, COPD
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality.
- Conditions
- Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia
- Trial name
- GARM-COVID19 (NCT04326036)
- Testing
- Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Black Tie Medical, Inc.
Idiopathic Pulmonary Fibrosis
Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF
A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic Pulmonary Fibrosis
- Trial name
- NCT04244825
- Testing
- BLD-2660
- Where
- United Kingdom
- Sponsor
- Blade Therapeutics
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part.
- Trial name
- NCT06360094
- Testing
- BI 1839100
- Where
- 99 sites in United States, Australia and 22 more
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim
Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe.
- Conditions
- Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
- Trial name
- NCT07201922
- Testing
- Nerandomilast
- Where
- 55 sites in United States, Argentina and 11 more
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
SARS-CoV-2 Infection, Fibrosis Lung
Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia
The innovative drug Treamid is planned for use in the rehabilitation of patients after COVID-19 pneumonia in a pilot, multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to assess the efficacy and…
- Trial name
- NCT04527354
- Testing
- Treamid
- Where
- 8 sites in Russia
- Volunteers
- 60 people
- Sponsor
- PHARMENTERPRISES LLC
Idiopathic Pulmonary Fibrosis
A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis
This Phase 2 study is to be conducted to evaluate the safety, tolerability, and activity of 400 mg of belumosudil orally (PO) once-daily (QD) compared to Best Supportive Care (BSC) in male and postmenopausal/surgically sterilized…
- Trial name
- NCT02688647
- Testing
- Belumosudil, BSC
- Where
- 10 sites in United States
- Volunteers
- 76 people
- Sponsor
- Kadmon Corporation, LLC